Kilitch Drugs (India) Ltd
Incorporated in 1978, Kilitch Drugs Ltd is engaged in the operation and management of Pharmaceutical Products[1]
- Market Cap ₹ 563 Cr.
- Current Price ₹ 350
- High / Low ₹ 470 / 248
- Stock P/E 55.3
- Book Value ₹ 110
- Dividend Yield 0.00 %
- ROCE 12.8 %
- ROE 7.83 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 35.1% CAGR over last 5 years
Cons
- Stock is trading at 3.00 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 5.90% over last 3 years.
- Company's cost of borrowing seems high
- Working capital days have increased from 61.3 days to 105 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
146 | 108 | 19 | 21 | 27 | 51 | 82 | 53 | 68 | 114 | 140 | 154 | 151 | |
124 | 95 | 21 | 25 | 28 | 45 | 75 | 53 | 63 | 104 | 122 | 130 | 132 | |
Operating Profit | 22 | 13 | -2 | -4 | -1 | 6 | 7 | 0 | 5 | 10 | 18 | 24 | 20 |
OPM % | 15% | 12% | -9% | -19% | -2% | 11% | 9% | 1% | 8% | 9% | 13% | 16% | 13% |
0 | 92 | 3 | 2 | 1 | 3 | 4 | 4 | 3 | 3 | 3 | 4 | 6 | |
Interest | 4 | 3 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 5 | 6 | 6 |
Depreciation | 6 | 5 | 2 | 10 | 10 | 2 | 2 | 2 | 2 | 2 | 4 | 3 | 3 |
Profit before tax | 13 | 97 | -1 | -12 | -9 | 6 | 9 | 2 | 5 | 10 | 12 | 19 | 17 |
Tax % | 20% | 22% | -70% | -4% | -5% | 16% | 55% | 48% | 27% | 35% | 31% | 30% | |
10 | 76 | -0 | -11 | -9 | 5 | 4 | 1 | 4 | 6 | 8 | 14 | 11 | |
EPS in Rs | 7.93 | 57.67 | -0.22 | -8.46 | -6.72 | 3.75 | 2.49 | 0.54 | 2.43 | 4.73 | 6.71 | 9.08 | 7.82 |
Dividend Payout % | 13% | 52% | 0% | 0% | 0% | 13% | 20% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 13% |
3 Years: | 31% |
TTM: | 6% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 35% |
3 Years: | 62% |
TTM: | 6% |
Stock Price CAGR | |
---|---|
10 Years: | 29% |
5 Years: | 23% |
3 Years: | 24% |
1 Year: | 25% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 4% |
3 Years: | 6% |
Last Year: | 8% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 13 | 13 | 13 | 13 | 13 | 14 | 15 | 15 | 15 | 16 | 16 | 16 |
Reserves | 71 | 101 | 107 | 95 | 88 | 98 | 106 | 103 | 112 | 121 | 131 | 160 |
16 | 9 | 0 | 0 | 1 | 1 | 9 | 13 | 15 | 20 | 22 | 32 | |
53 | 54 | 7 | 8 | 11 | 15 | 13 | 12 | 61 | 53 | 51 | 32 | |
Total Liabilities | 153 | 177 | 127 | 117 | 113 | 128 | 144 | 143 | 203 | 210 | 220 | 240 |
42 | 9 | 9 | 42 | 33 | 33 | 32 | 32 | 30 | 65 | 64 | 62 | |
CWIP | 43 | 0 | 0 | 0 | 1 | 3 | 20 | 30 | 65 | 3 | 4 | 6 |
Investments | 0 | 138 | 72 | 49 | 53 | 56 | 53 | 52 | 60 | 71 | 62 | 72 |
68 | 30 | 46 | 25 | 26 | 35 | 38 | 30 | 47 | 71 | 90 | 100 | |
Total Assets | 153 | 177 | 127 | 117 | 113 | 128 | 144 | 143 | 203 | 210 | 220 | 240 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
22 | -29 | -8 | 17 | 1 | 1 | 0 | 4 | 46 | 6 | 3 | -0 | |
-24 | 41 | -31 | -20 | -2 | -4 | -14 | -10 | -38 | -15 | 8 | -10 | |
7 | -9 | -0 | 0 | -0 | 6 | 17 | 1 | 2 | 7 | -1 | 9 | |
Net Cash Flow | 6 | 2 | -39 | -2 | -0 | 2 | 3 | -5 | 10 | -2 | 10 | -1 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 97 | 51 | 243 | 286 | 196 | 148 | 86 | 109 | 122 | 132 | 142 | 149 |
Inventory Days | 62 | 12 | 124 | 110 | 84 | 39 | 36 | 70 | 35 | 28 | 10 | 18 |
Days Payable | 37 | 19 | 124 | 154 | 184 | 108 | 33 | 89 | 525 | 239 | 200 | 118 |
Cash Conversion Cycle | 121 | 44 | 243 | 241 | 96 | 79 | 89 | 89 | -367 | -79 | -48 | 50 |
Working Capital Days | 19 | -114 | 197 | 237 | 124 | 100 | 79 | 108 | -144 | 25 | 54 | 105 |
ROCE % | 15% | 8% | -10% | -9% | 5% | 6% | 1% | 3% | 6% | 10% | 13% |
Documents
Announcements
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
13h - Intimation of duplicate share certificate issuance.
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 27 Sep
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
27 Sep - Proceedings of 32nd AGM held on 27th September 2024.
-
Closure of Trading Window
25 Sep - Closure of trading window from 1st October 2024.
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
21 Sep - Intimation of duplicate share certificate issuance.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Jun 2024TranscriptPPT
-
Jun 2023TranscriptPPT
Business Overview:[1]
KDL is a pharmaceutical company engaged in developing, manufacturing, marketing, and exporting various Pharmaceutical Formulations in dosage forms like Solid, Liquid, and Parental.